Chronic Myeloid Leukemia (CML) is a hematological disorder characterized by the neoplastic transformation of a hematopoietic stem cell carrying the Philadelphia (Ph) chromosome that juxtaposes the breakpoint cluster region (BCR) and the Abelson1 (ABL1) genes [1,2,3]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.